Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

Shattuck Labs, a clinical-stage biotechnology company developing DR3 blocking antibodies, announced the pricing of a public offering of 10.9 million shares at $4.00 per share and 7.9 million pre-funded warrants at $3.9999 per warrant, expected to raise approximately $75 million gross proceeds. The offering is expected to close on June 11, 2026, with Leerink Partners, J.P. Morgan, Piper Sandler, and Cantor serving as joint bookrunning managers.